George Demetri
Medical Oncology · Boston, MANPI 1841267093
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,474,112 of the $1,572,824 with a category attached, or 93.7%. Blueprint Medicines Corporation accounts for 79.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $478,313 and has fallen 86.2% since, to $65,881 in 2025. Among medical oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $10,348 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$1.2M
- Aadi Bioscience, Inc.$122K
- Merck Kgaa$50K
- Bayer$29K
- EMD Serono, Inc.$26K
- Daiichi Sankyo Inc.$16K
- plus $81K from 13 others
Across 59 payments — averaging $77,870 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.4M
- GSK$97K
- AbbVie$53K
- Daiichi Sankyo Company LTD$34K
- Bayer$22K
- F. Hoffmann-la Roche AG$8K
- plus $3K from 2 others
What the payments were for
- Consulting fees$1,474,11294%
- Speaking & faculty fees$83,4355%
- Travel & lodging$11,6501%
- Food & beverage$3,0920%
- Gifts$5350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 43 | $1,248,545 |
| Aadi Bioscience, Inc. | 19 | $122,099 |
| Merck Kgaa | 15 | $49,647 |
| Bayer | 9 | $29,100 |
| EMD Serono, Inc. | 11 | $26,208 |
| Daiichi Sankyo Inc. | 13 | $16,074 |
| Sumitomo Pharma America, Inc. | 3 | $12,720 |
| Mirati Therapeutics, Inc. | 2 | $12,495 |
| GSK | 10 | $12,142 |
| Pfizer | 1 | $10,002 |
| F. Hoffmann-la Roche AG | 14 | $9,893 |
| Ipsen Biopharmaceuticals, Inc | 5 | $8,538 |
| Sanofi | 1 | $5,000 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $3,300 |
| Jazz Pharmaceuticals Inc. | 1 | $2,880 |
| Genentech USA, Inc. | 1 | $2,640 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Daiichi Sankyo Company LTD | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FYARRO$51,923
- Stivarga$14,000
- Vitrakvi$12,650
- KRAZATI$12,495
- ONIVYDE$8,538
- TAZVERIK$8,388
- Non-Covered Product$5,603
- Non-Covered$3,500
- ZEPZELCA$2,880
- COSELA$1,500
How this compares
$1,572,824 in reported general payments places this provider in the 95th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Boston
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
- Reid MerrymanBoston$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.